IL18 and neoplasm: For example, it has been demonstrated that tumor-derived interleukin (IL)-18 increases the immunosuppressive CD56dimCD16dim/- NK cell fraction in patients with triple-negative breast cancer (TNBC) and induces the expression of PD-1 in these cells (36).